Although the predictability of an MRM headache attack lends itself to preventative treatment, there are currently no drugs specifically indicated for the prevention of MM. Such preventative therapies might be administered either short term (during the time around the period otherwise known as the peri-menstrual period or PMP) or continuously throughout the menstrual cycle. Frovatriptan has been developed for the management of migraine and is already licensed for use as an acute treatment for this condition. Previous well controlled clinical trials have highlighted the potential of frovatriptan as a short-term preventative medication for MM. This clinical trial was meant to further explore this indication for frovatriptan in an expanded population.
See above
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
DOUBLE
Enrollment
500
Primary endpoint Number of MRM headache free PMPs out of a potential of three treated PMPs
Incidence of MRM headache
Maximum headache intensity
Incidence of moderate or severe MRM headaches
Number of MRM headache free days during treated PMPs
Incidence of MRM headache associated symptoms (e.g. photophobia, phonophobia, nausea and vomiting)
Functional impairment during treatment phase
Time to onset (days) of MRM headache (during the treated PMP and until five days post treatment)
Time to onset of first post-treatment migraine Incidence of intercurrent migraine outside of the peri-menstrual period Use of rescue medication
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.